Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / RGS5

RGS5

Basics

Aliases:
This biomarker is also known as:
  • MSTP032,
  • MST129,
  • MSTP129,
  • MSTP106,
  • MSTP092,
  • MST092,
  • regulator of G-protein signaling 5,
  • MST106,
  • regulator of G-protein signalling 5,

View in BioMuta

Description…

RGS5 is a member of the regulators of G protein signaling (RGS) family, which are signal transduction molecules that are involved in the regulation of heterotrimeric G proteins by acting as GTPase activators. RGS5 has been found to be involved in tumor angiogenesis and to antagonize the angiogenic effect of VEGF. Multiple alternatively spliced transcript variants have been found.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

RGS5 has been found to be up-regulated in many types of malignant cells, including breast cancer.

Performance Comment

RGS5 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html